Adding a high dose of erythropoietin to therapeutic hypothermia did not reduce rates of death or disability in infants with neonatal hypoxic ischemic encephalopathy (HIE), a phase III randomized trial ...

Please provide your email address to receive an email when new articles are posted on . The phase 3 High-Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL) trial also demonstrated that ...

Whole-body hypothermia within hours of birth failed to improve outcomes in preterm infants less than 36 weeks' gestational age with hypoxic-ischemic encephalopathy. Death or moderate or severe ...

Please provide your email address to receive an email when new articles are posted on . Therapeutic hypothermia is frequently recommended for infants but mostly ineffective in premature newborns. “We ...

Therapeutic hypothermia, the only evidence-based treatment for newborns born with neonatal encephalopathy (NE) at or after 36 weeks, is not effective for reducing death or moderate/severe disability ...

Therapeutic hypothermia, the only evidence-based treatment for newborns born with neonatal encephalopathy (NE) at or after 36 weeks, is not effective for reducing death or moderate/severe disability ...

Among infants with neonatal encephalopathy (NE), exposure to early infection risk factors was not associated with a higher risk for death or major feeding problems. "Clinicians, faced with an infant ...

Hypoxic-ischemic encephalopathy (HIE) is one of the leading causes of newborn mortality and morbidity worldwide, and lowering the baby’s body temperature—called therapeutic hypothermia—is often used ...

For adults who have suffered a heart attack, the standard of care is to cool the body from 98 to 91 degrees Fahrenheit, called therapeutic hypothermia. The practice reduces brain and organ damage, and ...

The therapeutic hypothermia systems market grows with rising cardiac and neurological cases, surgical demand, and adoption of advanced cooling devices. BRENTFORD ...